DIMA
DIMA:
Leading product AF-29 is in late preclinical stage of development. Superior IL-1 signaling inhibition efficacy and prolonged PK were confirmed in rodent models. IND application is expected in Q2/2026.
AF-29
- Novel design of bispecific antibody enables blocking IL-1 signaling on inflammation relevant cells
- Superior potency compared with mAb competitorsacross multiple rodent models, including ~100-fold higher activity than IL-1β mAb Canakinumab
- Exhibited favorable pharmacokinetic and toxicology profiles in both rodents and NHPs
- No observable toxicity in NHP up to 150mg/kg dose level
- Optimized half-lives of the two binding motifs to balance efficacy and side effects, supporting Q4W dosing in human
- Favorable physiochemical and pharmacological properties, enabling subcutaneous administration
- Potential therapeutic application across multiple inflammatory and autoimmune diseases, either as monotherapy or in combination with existing treatments
- Completed process development to support manufacture of toxicity study and clinical trial material